18F-FDG-PET/CT in myelofibrosis

Nuklearmedizin 2011; 50(06): N66-N67
DOI: 10.1055/s-0037-1621653

Case report

Schattauer GmbH

¹⁸F-FDG-PET/CT in myelofibrosis

F. F. Behrendt

¹Department of Nuclear Medicine, University Hospital RWTH Aachen, Germany

,

T. Krohn

¹Department of Nuclear Medicine, University Hospital RWTH Aachen, Germany

,

M. Palmowski

¹Department of Nuclear Medicine, University Hospital RWTH Aachen, Germany

,

F. M. Mottaghy

¹Department of Nuclear Medicine, University Hospital RWTH Aachen, Germany

References
1 Amano Y, Onda M, Amano M, Kumazaki T. Magnetic resonance imaging of myelofibrosis. STIR and gadolinium-enhanced MR images. Clin Imaging 1997; 21: 264-268.
2 Burrell SC, Fischman AJ. Myelofibrosis on ¹⁸F FDG PET Imaging. Clin Nucl Med 2005; 30: 674.
3 Cervantes F, Barosi G, Demory JL. et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998; 102: 684-690.
4 Guermazi A, de Kerviler E, Cazals-Hatem D. et al. Imaging findings in patients with myelofibrosis. Eur Radiol 1999; 9: 1366-1375.
5 James C, Ugo V, Le Couedic JP. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
6 Khanna V, Nama S, Tailor R, Muthukrishnan A. Myelofibrosis on ¹⁸F-FD G-PET/CT in a case suspicious for post-transplant lymphoproliferative disorder. Hell J Nucl Med 2009; 12: 274-275.
7 Lanir A, Aghai E, Simon JS. et al. MR imaging in myelofibrosis. J Comput Assist Tomogr 1986; 10: 634-636.
8 Levine RL, Wadleigh M, Cools J. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
9 Tefferi A. Myelo fibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255-1265.